Thymosin Alpha-1
Clinical evidence — Human trial data existsWhat it is
A thymus-derived peptide (Zadaxin) approved in some countries as an immune modulator, with human trial data in hepatitis and as an adjuvant.
Thymosin Alpha-1 (Zadaxin) is a thymus-derived immune-modulating peptide, approved in some countries with human trial data in hepatitis and as a vaccine adjuvant.
Research context
Studied in relation to:
- Immune modulation
- Adjunct research in infection
Points in its favour in the literature:
- Approved in several countries
- Human clinical data exists
Caveats and unknowns:
- Not approved everywhere
- Research-grade differs from licensed product
- Use should be clinician-led
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature.
Published clinical / research context (not instructions)The Zadaxin label uses ~1.6 mg twice weekly; research protocols vary.
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 5 mg vial + 2 mL → 2.5 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 5mg | TA5 |
| 10mg | TA10 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.